OBJECTIVE: To probe into the effects of modified Chaihu Shugan powder combined with antiviral drugs on prognosis of patients with chronic hepatitis B（CHB）. METHODS: A total of 80 patients with CHB admitted into Shijiazhuang Maternity ＆ Child Healthcare Hospital from Aug. 2018 to Aug. 2021 were extracted to be divided into the western medicine group and combination group via the random number table method

with 40 cases in each group. The western medicine group was given conventional antiviral therapy

while the combination group received modified Chaihu Shugan powder combined with antiviral therapy. The traditional Chinese medicine（TCM） syndrome scores of two groups before treatment and at 12

24

and 48 weeks of treatment were compared

and the treatment response rate was observed after the course of treatment. Levels of hepatitis B virus deoxyribonucleic acid（HBV-DNA）

aspartate aminotransferase（AST）

alanine aminotransferase（ALT）

total bilirubin（TBIL）

and glutamyl transpeptide（GGT） were detected before treatment and at 12

24

and 48 weeks after treatment. At the same time

levels of serum interleukin（IL）-1β

IL-4 and tumor necrosis factor-α（TNF-α） were detected in two groups. Incidence of adverse drug reactions was recorded

and the incidence of liver fibrosis

liver cirrhosis

liver cancer and death were compared between two groups. RESULTS: The TCM syndrome scores in two groups at 12

24

and 48 weeks after treatment were lower than those before treatment

and the combination group was lower than the western medicine group

with statistically significant difference（P<0.05）. The overall response rate of the combination group was 92.50%（37/40）

higher than 75.00%（30/40） of the western medicine group

with statistically significant difference（P<0.05）. The levels of HBV-DNA

AST

ALT

TBIL

GGT

IL-1β

IL-4 and TNF-α in two groups after treatment for 12

24

and 48 weeks were lower than those before treatment（P<0.05）; the levels of HBV-DNA

AST

ALT

IL-1β and TNF-α in the combination group were lower than those in the western medicine group

the levels of TBIL and GGT at 24 and 48 weeks after treatment in the combination group were lower than those in the western medicine group

and the levels of IL-4 at 48 weeks after treatment in the combination group were lower than those in the western medicine group（P<0.05）

with statistically significant differences. The incidence of adverse drug reactions in the combination group was 15.00%（6/40）

which was not statistically different from 10.00%（4/40） in the western medicine group（P>0.05）. The incidence of disease progression events in the combination group was 2.50%（1/40）

lower than 20.00%（8/40） in the western medicine group

with statistically significant difference（P<0.05）. CONCLUSIONS: Modified Chaihu Shugan powder combined with antiviral therapy can promote the improvement of symptoms in patients with CHB and increase the treatment response rate

which may achieve the purpose of treatment by improving liver function and inhibiting the levels of IL-1β

IL-4 and TNF-α

and can control the risk of disease progression events with higher medication safety.